Page last updated: 2024-12-11
bay x 7195
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BAY x 7195: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6442328 |
| CHEMBL ID | 314115 |
| SCHEMBL ID | 156423 |
| MeSH ID | M0243643 |
Synonyms (14)
| Synonym |
|---|
| bay-x-7195 |
| CHEMBL314115 |
| ugwpb2qit9 , |
| bay x 7195 |
| bay x-7195 |
| (s)-4-(4-carboxyphenylthio)-7-(4-(4-phenoxybutyloxy)phenyl)-5-(z)-heptenoic acid |
| unii-ugwpb2qit9 |
| 143538-27-6 |
| SCHEMBL156423 |
| bay-x 7195 |
| benzoic acid, 4-(((1s,2z)-1-(2-carboxyethyl)-4-(4-(4-phenoxybutoxy)phenyl)-2-butenyl)thio)- |
| benzoic acid, 4-((1-(2-carboxyethyl)-4-(4-(4-phenoxybutoxy)phenyl)-2-butenyl)thio)-, (s-(z))- |
| 4-(4-carboxyphenylthio)-7-(4-(4-phenoxybutoxy)-phenyl)-5(z)-heptene acid,d- |
| 4-[(z,3s)-1-carboxy-6-[4-(4-phenoxybutoxy)phenyl]hex-4-en-3-yl]sulfanylbenzoic acid |
Research Excerpts
Overview
BAY x 7195 is a novel receptor antagonist of cysteinyl-leukotrienes currently under development for the treatment of asthma.
| Excerpt | Reference | Relevance |
|---|---|---|
| "BAY x 7195 is a novel receptor antagonist of cysteinyl-leukotrienes currently under development for the treatment of asthma. " | ( Pharmacokinetics, safety and tolerability of the orally administered receptor antagonist of cysteinyl-leukotrienes BAY x 7195 in single-dose escalation studies. Heinig, R; Kuhlmann, J; Schaefer, HG; Wensing, G, 1995) | 1.94 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The only remarkable adverse event was diarrhea in one volunteer receiving the highest dose of 1000 mg." | ( Pharmacokinetics, safety and tolerability of the orally administered receptor antagonist of cysteinyl-leukotrienes BAY x 7195 in single-dose escalation studies. Heinig, R; Kuhlmann, J; Schaefer, HG; Wensing, G, 1995) | 0.5 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " In spite of substantial inter-subject variability intra-individual variability in AUC and Cmax was reasonable." | ( Pharmacokinetics, safety and tolerability of the orally administered receptor antagonist of cysteinyl-leukotrienes BAY x 7195 in single-dose escalation studies. Heinig, R; Kuhlmann, J; Schaefer, HG; Wensing, G, 1995) | 0.5 |
| " The pharmacodynamic effect was assessed by testing the ability of BAY x 7195 aerosol to inhibit leukotriene-D4 (LTD4) induced bronchoconstriction in healthy volunteers." | ( Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers. Heinig, R; Kuhlmann, J; Wensing, G, 1996) | 0.8 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID79849 | Compound was tested for LTD4 induced guinea pig trachea contraction. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID91227 | Compound was shown 8 fold shift in LTD4 dose response curve 2 hours after 250 mg oral dose. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.62) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (45.45%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (45.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||